Usona Institute

Compass Pathways to cut 30% of workforce, halt early-stage research, and focus on COMP360 Phase 3 trials; net loss widens to $38.5M; top-line data expected Q2 2025; COMP006 results delayed to H2 2026 due to increased regulatory scrutiny; restructuring follows RBC Capital Markets' 'Outperform' rating; co-founder George Goldsmith sells shares to former co-founder Lars Wilde; faces competition from Cybin Inc. and Usona Institute; R&D costs rise to $32.9M; cash reserves expected to fund operations into 2026.

E.E.S. directs Instituto Phaneros and advises Reconnect Foundation; F.K. has received support from Tryp Therapeutics, holds stocks and consults for Cybin, holds stocks in Compass Pathways, and advises Apex Labs. Other authors declare no conflicts.

Psilocybin, found in magic mushrooms, shows promise in treating clinical depression when combined with therapy, according to Wisconsin researchers. Estimates suggest 6 million U.S. patients could benefit if approved, though challenges include cost and regulatory hurdles.

The DEA proposed increasing psilocybin, psilocin, and ibogaine production quotas by 50% for 2025, signaling support for psychedelic research. This follows a growing interest in studying these compounds for mental health treatments, despite their Schedule 1 status. The VA is also increasingly involved in psychedelic-assisted therapy research for veterans.